BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Maxim Pharmaceuticals, Inc. (MAXM) Announces Initiation Of New Apoptosis Screening Campaign And Publication Of Manuscript In Journal Of Medicinal Chemistry


10/19/2005 5:13:16 PM

SAN DIEGO--(BUSINESS WIRE)--April 12, 2005--Maxim Pharmaceuticals, Inc. (NASDAQ:MAXM)(SSE:MAXM) announced today the initiation of a new screening campaign using approximately 60,000 compounds recently acquired for its compound library to identify potential new anticancer agents and novel molecular targets for inducing apoptosis in cancer cells. As with other compounds in Maxim's library, the new compounds are not subject to any financial or legal restrictions aside from the cost of purchase. By synthesis of analogs of the initial hit to improve potency and other pharmacologic properties, Maxim establishes a broad and proprietary intellectual property position on any potential lead compound candidate. The Company has already identified four novel potential cancer drug candidates from prior screening activities. The most advanced of the lead compounds has entered the clinical development through a partnership with Myriad Genetics, and the others are expected to move into the clinic over the next 12 to 18 months, either independently or through additional collaborations.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES